Esbriet (pirfenidone) is an anti-fibrotic and anti-inflammatory drug used in the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). Manufactured by Genentech and given FDA approval in 2014, the drug reduces the amount of lung fibrosis by blocking secretions responsible for excessive collagen production. It also reduces inflammation in the lungs.
Here are some of the most frequently asked questions about the drug from esbriet.com:
How will Esbriet help me?
Esbriet has been shown to prolong life for IPF patients by slowing down the progression of the disease. A one-year clinical trial found that Esbriet improved lung stability in 23 percent of patients, compared to 10 percent of patients not taking the drug.